Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Sitagliptin

Sitagliptin

pharmaceutical raw materials
Sitagliptin structure

Sitagliptin 

structure
  • CAS No:

    486460-32-6

  • Formula:

    C16H15F6N5O

  • Chemical Name:

    Sitagliptin

  • Synonyms:

    1-Butanone,3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-,(3R)-;1,2,4-Triazolo[4,3-a]pyrazine,7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-;(3R)-3-Amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-1-butanone;(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine;Sitagliptin;3(R)-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine;(3R)-3-Amino-1-[3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;(3R)-3-Amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;Xelevia;Tesavel;Ristaben

  • Categories:

    Active Pharmaceutical Ingredients  >  Circulatory System Drugs

Description

Sitagliptin is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts.

Sitagliptin Basic Attributes

407.32

407.31

1308068-626-2

Characteristics

77

1.5

Solid

1.6±0.1 g/cm3

114.1-115.7 °C

529.9±60.0 °C at 760 mmHg

274.3±32.9 °C

1.590

3.40e-02 g/L

Store at 20-25 deg C (68-77 deg F), excursions permitted to 15-30 deg C (59-86 deg F).

2.91X10-8 mm Hg at 25 deg C (est)

Safety Information

Stable if stored as directed; avoid strong oxidizing agents. /Sitagliptin phosphate monohydrate/

Sitagliptin Use and Manufacturing

Sitagliptin is a new type of anti-type II diabetes drug approved by the FDA and the first dipeptidyl peptidase-IV inhibitor drug used to treat type II diabetes. Sitagliptin's mechanism of action is different from previous oral hypoglycemic drugs. It improves the ability of diabetic patients' own pancreatic β cells to produce insulin and increases insulin secretion when blood sugar rises, thereby controlling the blood sugar level of diabetic patients. Clinical studies have shown that sitagliptin is an orally effective drug with good market prospects. It has a significant hypoglycemic effect when used alone or in combination with metformin and pioglitazone, and it is safe to take, well tolerated, and has fewer adverse reactions.

Computed Properties

Molecular Weight:407.31
XLogP3:0.7
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:10
Rotatable Bond Count:4
Exact Mass:407.11807909
Monoisotopic Mass:407.11807909
Topological Polar Surface Area:77
Heavy Atom Count:28
Complexity:566
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Related Drugs

Registered Holders

  • ZYDUS LIFESCIENCES LTD

    United States United States
    Active
  • MOEHS IBERICA SL

    United States United States
    Active
  • JIANGSU BAJU PHARMACEUTICAL CO LTD

    United States United States
    Active

Recommended Suppliers of Sitagliptin

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.